Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 9Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Solid Tumor, Adult 1Recurrence 1Rectal Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neutropenia 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Cystadenocarcinoma, Serous 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

niraparib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cystadenocarcinoma, Serous × niraparib × Clear all
NCT04159155 2025-08-12

CAN-STAMP

University Health Network, Toronto

Phase 2/3 Terminated
11 enrolled
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡